SCHEMBL7576836

SCHEMBL7576836

C=C1CN(C(=O)OCc2ccccc2)[C@](CO[SiH](C)C)(C(C)(C)C)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
AGTR2 P50052 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CTRB1 P17538 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
P2RX4 Q99571 2/20 0.34
CYP2C19 P33261 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
DRD1 P21728 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8701753 0.88 NPC1 (0.42) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL8701759 0.88 NPC1 (0.42) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL3295186 0.79 HTR2C (0.40) HTR2CNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8699834 0.79 HTR2C (0.40) HTR2CNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL27589260 0.72 NPC1 (0.41) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL2435139 0.71 SMN1; SMN2 (0.46) HTR2CNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL13378377 0.70 MEN1 (0.37) MEN1KMT2AALDH1A1
SCHEMBL2430964 0.69 SMN1; SMN2 (0.45) HTR2CNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1365210 0.67 ELANE (0.41) HTR2CAGTR2PDK1PDK2PDK3
SCHEMBL4058433 0.67 ALDH1A1 (0.50) HTR2CNPC1RAB9ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888344-A1 SPIROCYCLE INTEGRIN INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1999-01-07 EP disclosed
US-5760029-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 US disclosed
WO-1997033887-A1 SPIROCYCLE INTEGRIN INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1997-09-18 WO disclosed